{"prompt": "['Non-Interventional Study Protocol', 'Study Short Title', 'Evaluation of the sensitivity and specificity of a novel quality of life (QoL)', 'tool to assess the treatment satisfaction in psoriasis patients', 'STUDY IDENTIFICATION No. 2020-A00652-37', 'Full Study Title', 'Evaluation of the sensitivity and specificity, compared to DLQI as a standard tool, of a novel', 'QoL questionnaire (treat to the PSOriasis patient satiSfactiOn TARGET) among moderate to', 'severe psoriasis patients treated with brodalumab (Kyntheum)', 'GPP statement:', 'This Non-Interventional Study will be conducted in compliance with the', 'Clinical Study Protocol, Good Pharmacoepidemiology Practices and', 'applicable regulatory requirement(s)', 'Sponsoring entity:', 'LEO Study ID: PSO-TARGET', 'LEO Pharma France', '2 rue Ren\u00e9 Caudron', 'Date: 25-05-2020', '215 avenue Georges Clemenceau', '78960 Voisins-Le-Bretonneux', 'Version: 2.0']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 2 of 51', 'Study ID RCB: 2020-A00652-37', 'KEY STUDY PERSONNEL', 'STUDY MANAGER', 'MAIN PROTOCOL AUTHOR', 'BERTRAND B\u00e9n\u00e9dicte, Clinical Manager', 'SALTET DE SABLET Thibaut, Medical Writer', 'CLINACT', 'CLINACT', 'V\u00e9lizy Espace - Immeuble Santos Dumont', 'V\u00e9lizy Espace - Immeuble Santos Dumont', '13 avenue Morane Saulnier - CS 50730', '13 avenue Morane Saulnier - CS 50730', '78457 V\u00e9lizy-Villacoublay Cedex, France', '78457 V\u00e9lizy-Villacoublay Cedex, France', 'STATISTICIAN', 'CARRERE Florence, Head of Biometry /', 'Senior Biostatistician', 'STATITEC', 'V\u00e9lizy Espace - Immeuble Santos Dumont', '13 avenue Morane Saulnier - CS 50730', '78457 V\u00e9lizy-Villacoublay Cedex, France', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 3 of 51', 'Study ID RCB: 2020-A00652-37', 'APPROVERS', 'The following person(s) within LEO Pharma (LEO) has/have approved this Study Protocol by', 'signing the Non-Interventional Study Protocol Approval Form adjoined as a separate page to', 'this document:', 'Nadine MacKenzie', 'Medical director, France and Benelux', 'NV', 'Sarah Moumane', 'Dermatology MSL manager, France', 'LIMAY', 'Ang\u00e8le GUILBOT', 'Scientific and Regulatory Director', 'CLINACT', 'V\u00e9lizy Espace - Immeuble Santos Dumont', 'Apple', '13 avenue Morane Saulnier - CS 50730', '78457 V\u00e9lizy-Villacoublay Cedex, France', 'Dr Ziad REGUIAI', 'International Co-ordinating Investigator', 'Polyclinique Reims-Bezannes', 'A', '89 Rue Victor De Broglie', '51430 Bezannes, FRANCE', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 4 of 51', 'Study ID RCB: 2020-A00652-37', '1', 'Table of Contents', '1 Table of Contents', '4', '2 List of Abbreviations', '7', '3 Responsible Parties', '8', '4 Abstract', '10', '5 Amendments and Updates', '15', '6 Milestones', '16', '7 Rationale and Background', '16', '8 Research Question and Objectives', '20', '8.1 Primary Objective', '20', '8.2 Secondary Objectives', '20', '9 Research Method', '20', '9.1', 'Study Design', '20', '9.1.1', 'Eligibility criteria', '20', '9.1.2', 'PSO-TARGET Quality of Life Component grid.', '21', '9.1.3', 'Dermatology Quality of Life Index (DLQI)', '22', '9.1.4', 'Limitation of bias', '23', '9.1.5', 'Study Schedule', '23', '9.1.6', 'Definition of a non-interventional study', '24', '9.2 Setting', '25', '9.3 Variables', '26', '9.4', 'Data Source', '28', '9.5', 'Study Size', '29', '9.6 Data Management', '30', '9.7', 'Data Analysis', '32', '9.8', 'Statistical Analysis Plan', '32', '9.8.1', 'Description of the population', '32', '9.8.2', 'Baseline characteristics', '33', '9.8.3', 'Sensitivity/sensibility analysis', '33', '9.8.4', 'Efficacy analysis', '35', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 5 of 51', 'Study ID RCB: 2020-A00652-37', '9.8.5', 'Other secondary analyses', '36', '9.8.6', 'Safety analysis', '39', '9.9', 'Quality Control', '39', '9.9.1', 'Data Collection', '39', '9.9.2', 'Data monitoring', '39', '9.9.3', 'Data validation', '40', '9.10 Limitations of Research Methods', '40', '9.11 Other Aspects', '41', '10 Protection of human subjects', '41', '11 Management and Reporting of Adverse Events and Other Experiences', '44', '11.1 Definitions', '44', \"11.2 Physician's responsibility for reporting of Adverse Drug Reactions, Adverse Events and\", 'Other Experiences', '45', '11.3 LEO responsibilities for reporting of safety-related data', '47', '12 Plans for Disseminating and Communicating Study Results', '47', '13 References', '48', 'Annex 1. PSO-TARGET Component Grid', '51', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}